Alzheimer’s disease may be a disaster for all it strikes, but we may be that much closer to being able to more effectively treat it thanks to new word from healthcare stock Cognition Therapeutics (NASDAQ:CGTX). Said new word—which appeared in the medical journal Translational Neurodegeneration—detailed how its latest treatment option is turning out in testing. This caused share prices to go up almost 15% in Thursday’s trading.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The word out of the phase 1b study turned out to match up to studies done on transgenic mice. Just a single dose of the Cognition treatment—named CT1812—rapidly got rid of A-Beta oligomers near brain synapses. By way of comparison, a placebo showed absolutely no movement of those same oligomers, which meant that CT1812 was definitely doing its job. Better yet, CT1812 proved easily tolerated and didn’t offer up any serious adverse effects. There were some adverse effects, but these were mainly due to a side condition related to installing an indwelling catheter that collects cerebrospinal fluid.
This was enough for Cogition’s chief medical officer and head of research and development, Anthony Caggiano, MD, Ph.D., to come out strongly in favor of CT1812. Caggiano noted that what was found so far was enough to make the Phase 2 study look all the better and should produce positive results as well.
A look at the last five days in trading for Cognition Therapeutics stock, meanwhile, shows something of a volatile position in progress. You can see several up-and-down movements, though these are within a comparatively tight range of about $0.20 in any direction. Yet when the news of CT1812’s success hit, shares ramped upward nicely to hit a new plateau around the $2 mark.
